EQS-News

TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare

EQS-News: neurocare group AG / Key word(s): Investment TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare 24.04.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare

neurocare is revolutionizing mental health care by providing innovative methods and tools based on neurostimulation and other technologies to help clinicians deliver personalized treatments with sustainable clinical outcomes for patients.  The investment will enable the company to execute on its growth plans, including expansion into the MENA region.

Dubai, Munich - 24. April 2024 - TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and Singapore, today announced a EUR 16 million investment into Munich-headquartered neurocare group AG (neurocare), a leading innovator in personalized mental health care, providing solutions to empower clinicians to deliver best care to their patients. TVM Capital Healthcare's investment will enable neurocare to execute on its international growth plans, including expansion in the US and market entry into the Kingdom of Saudi Arabia, as well as support the development of new hardware and software innovations. It is the ninth investment of TVM Capital Healthcare to improve local access to quality healthcare in the MENA region.

neurocare, through its digital therapy platform (DTP), provides a holistic and patient centric treatment for a variety of psychological or neurological conditions. It uses innovative mental health care methods and tools including sleep assessment, therapeutics, psychotherapy, TMS and neurofeedback, all supervised within a cloud-based solution, to empower clinicians and deliver individualized care. Following a detailed assessment of the patient's condition, neurocare supports clinicians in developing individualized therapy plans that are designed to lead to strong, sustainable clinical outcomes. neurocare’s offering is used in the Company’s own clinics in the US, Europe and Australia, as well as in a growing number of third-party clinics globally.